HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on aTyr Pharma (NASDAQ:LIFE) and maintained a $35 price target.
September 21, 2023 | 10:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
aTyr Pharma's stock rating has been reiterated as Buy by HC Wainwright & Co. with a maintained price target of $35.
The reiteration of a Buy rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $35 indicates that the firm believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100